Literature DB >> 30132231

Disulfiram enhanced delivery of orally administered copper into the central nervous system in Menkes disease mouse model.

Takao Hoshina1, Satoshi Nozaki2, Takashi Hamazaki3, Satoshi Kudo3, Yuka Nakatani2, Hiroko Kodama4, Haruo Shintaku3, Yasuyoshi Watanabe2.   

Abstract

INTRODUCTION: Menkes disease (MD) is an X-linked recessive disorder caused by dysfunction of a copper-transporting protein, leading to severe neurodegeneration in early childhood. We investigated whether a lipophilic copper chelator, disulfiram, could enhance copper absorption from the intestine and transport copper across the blood-brain barrier in MD model mice.
METHODS: Wild type and MD model mice were pretreated with disulfiram for 30 min before oral administration of 64CuCl2. Each organ was sequentially analyzed for radioactivity with γ counting. Copper uptake into the brain parenchyma was assessed by ex vivo autoradiography.
RESULTS: In wild type mice, orally administered copper was initially detected in the intestine within 2 h, reaching a maximum level in the liver (19.6 ± 3.8 percentage injected dose per gram [%ID/g]) at 6 h. In MD model mice, the copper reached the maximum level in the liver (5.3 ± 1.5 %ID/g) at 4 h, which was lower than that of wild type mice (19.0 ± 7.4 %ID/g) (P < 0.05). Pretreatment of disulfiram in MD model mice increased the copper level in the brain (0.59 ± 0.28 %ID/g) at 24 h compared with MD model mice without disulfiram (0.07 ± 0.05 %ID/g) (P < 0.05). Ex vivo autoradiography revealed that high levels of copper uptake was observed in the cerebral cortex upon disulfiram pretreatment.
CONCLUSION: Our data demonstrated that disulfiram enhanced the delivery of orally administered copper into the central nervous system in MD model mice. The administration of disulfiram will enable patients to avoid unpleasant subcutaneous copper injection in the future.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30132231     DOI: 10.1007/s10545-018-0239-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  26 in total

1.  Effect of copper and disulfiram combination therapy on the macular mouse, a model of Menkes disease.

Authors:  Wattanaporn Bhadhprasit; Hiroko Kodama; Chie Fujisawa; Tomoko Hiroki; Eishin Ogawa
Journal:  J Trace Elem Med Biol       Date:  2012-06-02       Impact factor: 3.849

2.  A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration.

Authors:  J H MENKES; M ALTER; G K STEIGLEDER; D R WEAKLEY; J H SUNG
Journal:  Pediatrics       Date:  1962-05       Impact factor: 7.124

3.  Menkes' kinky hair disease: further definition of the defect in copper transport.

Authors:  D M Danks; E Cartwright; B J Stevens; R R Townley
Journal:  Science       Date:  1973-03-16       Impact factor: 47.728

4.  A serine-to-proline mutation in the copper-transporting P-type ATPase gene of the macular mouse.

Authors:  M Mori; M Nishimura
Journal:  Mamm Genome       Date:  1997-06       Impact factor: 2.957

5.  Copper metabolism disorders affect testes structure and gamete quality in male mice.

Authors:  Małgorzata Kowal; Małgorzata Lenartowicz; Anna Pecio; Aniela Gołas; Teresa Błaszkiewicz; Jozéfa Styrna
Journal:  Syst Biol Reprod Med       Date:  2010-09-17       Impact factor: 3.061

6.  Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase.

Authors:  C Vulpe; B Levinson; S Whitney; S Packman; J Gitschier
Journal:  Nat Genet       Date:  1993-01       Impact factor: 38.330

7.  Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.

Authors:  Jiayi Huang; Jian L Campian; Amit D Gujar; Christina Tsien; George Ansstas; David D Tran; Todd A DeWees; A Craig Lockhart; Albert H Kim
Journal:  J Neurooncol       Date:  2018-01-27       Impact factor: 4.130

8.  Copper-histidine therapy for Menkes disease.

Authors:  B Sarkar; K Lingertat-Walsh; J T Clarke
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

9.  Genetic expression of Menkes disease in cultured astrocytes of the macular mouse.

Authors:  H Kodama; Y Meguro; T Abe; M H Rayner; K T Suzuki; S Kobayashi; M Nishimura
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

10.  PET imaging analysis with 64Cu in disulfiram treatment for aberrant copper biodistribution in Menkes disease mouse model.

Authors:  Shiho Nomura; Satoshi Nozaki; Takashi Hamazaki; Taisuke Takeda; Eiichi Ninomiya; Satoshi Kudo; Emi Hayashinaka; Yasuhiro Wada; Tomoko Hiroki; Chie Fujisawa; Hiroko Kodama; Haruo Shintaku; Yasuyoshi Watanabe
Journal:  J Nucl Med       Date:  2014-03-13       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.